BRIEF published on 10/01/2024 at 00:56, 1 month 20 days ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
BRIEF published on 10/01/2024 at 00:45, 1 month 20 days ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
PRESS RELEASE published on 10/01/2024 at 00:40, 1 month 20 days ago Inside Information: News release on accounts, results Valerio Therapeutics reports its half-year 2024 financial results and updates on its activities, including the acquisition of Emglev Therapeutics and progress on the VIO-01 trial Acquisition Financial Results Valerio Therapeutics VIO-01 Trial Emglev Therapeutics
PRESS RELEASE published on 09/30/2024 at 22:40, 1 month 20 days ago Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
BRIEF published on 08/05/2024 at 19:23, 3 months 15 days ago Half-yearly review of the liquidity contract with Kepler Cheuvreux Liquidity Contract Transactions Kepler Cheuvreux AMF Valerio Therapeutics
PRESS RELEASE published on 08/05/2024 at 19:18, 3 months 15 days ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Valerio Therapeutics releases half-year liquidity contract statement revealing shares and trading volumes Liquidity Contract Shares AMF Decision Valerio Therapeutics Trading Volumes
BRIEF published on 06/05/2024 at 07:05, 5 months 16 days ago Minutes of the general meeting of Valerio Therapeutics Biotechnology Voting Results General Meeting Resolutions Valerio Therapeutics
PRESS RELEASE published on 06/05/2024 at 07:00, 5 months 16 days ago Inside Information / Other news releases Valerio Therapeutics reports successful Combined General Meeting with 48.1% quorum, adopting all resolutions. Consolidated vote results and meeting minutes to be available on the Company's website Euronext Growth Paris Biotechnology General Meeting Valerio Therapeutics DDR Drugs
BRIEF published on 05/22/2024 at 20:51, 5 months 29 days ago Valerio Therapeutics Advances VIO-01 Clinical Trial with Positive Results Drug Development Solid Tumors Clinical Trial Valerio Therapeutics VIO-01
PRESS RELEASE published on 05/22/2024 at 20:46, 5 months 29 days ago Inside Information / Other news releases Valerio Therapeutics completes dosing for first cohort of subjects in Phase 1/2 VIO-01 trial for solid tumors, showing encouraging tolerability. Phase 1b aims to determine recommended dose in selected solid tumors Solid Tumors Valerio Therapeutics VIO-01 Trial Phase 1/2 DNA Damage Response
Published on 11/21/2024 at 10:03, 25 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 28 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 28 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 53 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 3 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:04, 23 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 26 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 28 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 28 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 27 minutes ago Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 06:58, 3 hours 30 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 8 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 43 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 43 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
